Nature Medicine, Published online: 15 July 2026; doi:10.1038/s41591-026-04491-7
In a human clinical trial, repeated administration of an oligonucleotide–siRNA conjugate targeting SOD1 exhibited a favorable safety profile in six patients with SOD1-ALS.
